PCSK9 inhibitors in the management of atherosclerotic cardiovascular disease: Current clinical trials and future directions

Atherosclerosis. 2024 Nov 2:399:119043. doi: 10.1016/j.atherosclerosis.2024.119043. Online ahead of print.

Authors

Wenyi Nie¹, Yingbin Yue², Jingqing Hu³

Affiliations

¹ Changchun University of Chinese Medicine, Changchun, 130117, China. Electronic address: [email protected].
² The First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830054, China; State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Xinjiang Medical University, Urumqi, 830054, China.
³ Changchun University of Chinese Medicine, Changchun, 130117, China. Electronic address: [email protected].

PMID: 39536470
DOI: 10.1016/j.atherosclerosis.2024.119043

No abstract available

Keywords: Clinical trial; Existing evidence; Future perspectives; PCSK9 inhibitors.

Publication types

Letter